Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Company Limited American Depositary Shares (each
(NY:
TAK
)
16.72
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
20
21
Next >
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
May 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
April 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
↗
April 22, 2022
Via
Benzinga
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
↗
January 31, 2022
The
Via
Benzinga
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
April 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine
↗
April 21, 2022
NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials.
Via
InvestorPlace
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
April 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report
↗
April 18, 2022
Via
Benzinga
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
April 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference
↗
April 13, 2022
Via
Benzinga
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027
April 13, 2022
Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent...
Via
FinancialNewsMedia
Takeda Announces Completion of Acquisition of Own Shares
April 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
↗
April 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
April 12, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
April 05, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Monday Markets News
↗
March 28, 2022
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved.
Via
Talk Markets
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
March 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
↗
March 08, 2022
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID...
Via
Benzinga
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
February 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
↗
February 22, 2022
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...
Via
Benzinga
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
↗
February 22, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four...
Via
Benzinga
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
↗
February 18, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of...
Via
Benzinga
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2
February 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The Best Russell 2000 Stocks to Buy Before they Rebound
↗
February 15, 2022
Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.
Via
InvestorPlace
Why Are Seagen Shares Sinking Today?
↗
February 10, 2022
Seagen Inc (NASDAQ: SGEN) reported Q4 revenues
Via
Benzinga
Take a Leap Into Novavax Stock After Vaccine Sales Start
↗
February 08, 2022
Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch.
Via
InvestorPlace
A News Blizzard
↗
February 04, 2022
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs.
Via
Talk Markets
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
February 03, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
January 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Worldwide Adoption of Novavax Vaccines Makes It a Winner
↗
January 21, 2022
Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels.
Via
InvestorPlace
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
